We are always grateful for your understanding and support for FIRM’s activities.
Now, we are pleased to announce that Ken-ichiro Hata, President & CEO of Japan Tissue Engineering Co., Ltd., was appointed Chairperson and Representative Director at the Board of Directors meeting held after General Meeting on June 9, 2025.
We also announce that Hideto Yamaguchi, Senior Vice President, Head of Chemical & Biological Technology Labs., Head of Tsukuba Bio Research Center CMC Development of Astellas Pharma Inc., was appointed Vice Chairperson and Representative Director.
Going forward, we will strive for further development of regenerative medicine under this new system. We would like to ask for your continued kindness.